ArticleNature cancer2023

Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab.

Arash Nabbi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.